CA-AGENDIA-INC
11.12.2020 15:47:12 CET | Business Wire | Press release
Agendia, Inc. , a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van ’t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). These data highlight the ability of MammaPrint® , Agendia’s 70-gene breast cancer recurrence assay, to further stratify patients with clinically low risk breast cancer which could impact physician-patient discussions and treatment planning.
MINDACT (Microarray In Node-Negative and 1-3 node-positive Disease may Avoid ChemoTherapy), the Phase 3, prospective, randomized clinical trial supported by the European Organization for Research and Treatment of Cancer (EORTC), was designed to determine whether MammaPrint could be used to safely de-escalate patients with early stage breast cancer from chemotherapy without compromising their outcomes. Updated outcome and treatment data from the trial shared at SABCS 2020 build upon nearly 9-year follow-up results debuted at ASCO 2020 and confirm MINDACT as a positive de-escalation study.
Dr. van ’t Veer’s presentation showed that the combination of clinical low risk and MammaPrint Low Risk results indicate excellent 8-year prognosis – these patients showed a distant metastasis-free survival rate of 94.7% with no chemotherapy. Of note, amongst the clinically low risk study population, distant metastasis free survival at 8 years was 3.6% better in MammaPrint Low Risk patients as compared to those with a High Risk result.
“Collectively, these data produce a significant library of evidence that will allow for the precise treatment of breast cancer, including insights into a patient population considered low risk,” said Dr. van ’t Veer. “Within this population, further stratification by genomic signature into MammaPrint Low or High Risk should be weighed for further treatment planning.”
These data are part of a large suite of 13 posters, spotlight sessions and an oral presentation on MammaPrint and BluePrint that were accepted to SABCS 2020, and underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint® , the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint® , the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201211005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Money20/20 Europe Celebrates Ten Years of Industry Leadership as AI, Digital Assets and Financial Sovereignty Take Centre Stage8.6.2026 17:37:00 CEST | Press release
Money20/20, the world's leading fintech show and the place where money does business, celebrated a major milestone with its 10th Europe edition, convening more than 7,500 attendees, one in three at C-suite level, and over 2,300 companies from over 105 countries in Amsterdam, for three days of industry-defining announcements, strategic partnerships, and dealmaking that set the agenda for the future of financial services. Featuring more than 450 speakers across six stages, Money20/20 Europe welcomed leaders from banking, fintech, payments, policy, technology and digital assets to explore the forces reshaping the future of money. “This year’s show demonstrated that financial services have entered a new phase of transformation,” said Bryony Naylor, Vice President of Money20/20 Europe. “Across the show floor and on stage, we saw leaders move beyond discussing what’s next to actively building it. From AI and digital identity to financial sovereignty and digital assets, the conversations and
Liberty Latin America Selects BTS as Exclusive A2P Messaging Managed Services Partner Across All Its Markets8.6.2026 17:36:00 CEST | Press release
BTS announced today that it has been chosen as the exclusive provider of managed A2P SMS services for Liberty Latin America (LLA), supporting the company’s efforts to strengthen revenue protection, fraud mitigation, traffic intelligence, and operational visibility across its markets. The agreement reinforces LLA’s A2P messaging strategy throughout a broad regional footprint and establishes a coordinated operating model to improve control, visibility, and monetization of A2P traffic across its markets. The partnership will support revenue maximization, stronger fraud protection and grey-route mitigation, enhanced real-time traffic visibility, operational reporting and analytics, revenue assurance, and 24x7x365 managed services support. The agreement spans 25 markets and reflects a high level of operational trust in BTS’ ability to deliver consistent performance across diverse regulatory, technical, and commercial environments. “This agreement gives us a stronger and more consistent oper
The Estée Lauder Companies Strengthens UK Manufacturing Network as Whitman Facility Celebrates 60 Years of British Craftsmanship8.6.2026 17:14:00 CEST | Press release
As The Estée Lauder Companies’ (NYSE: EL) Whitman manufacturing facility celebrates its 60th anniversary, the company today announced a strategic investment that will strengthen its UK manufacturing network, further reinforcing its long-standing commitment to British craftsmanship, innovation, and growth in prestige fragrance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608415843/en/ From left to right: Jo Dancey, Global Brand President, Jo Malone London; Alex Gregorian, SVP, Global Manufacturing & Engineering; Roberto Canevari, Chief Value Chain Officer; Nadine Graf, President, EUKEM; Stéphane de La Faverie, President and Chief Executive Officer; William P. Lauder, Chair of the Board of Directors; Maria Genouzos, VP, EUKEM and APAC Manufacturing; Pernilla Nyberg, SVP, General Manager, UK & Ireland; Jamal Chamariq, SVP, EUKEM & TR Value Chain; and Ben Smith, Whitman Plant Manager, celebrate the 60th anniversary of The
IQM and Real Asset Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination8.6.2026 16:16:00 CEST | Press release
RAAQ Extraordinary General Meeting Scheduled for June 25, 2026 IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced today that the registration statement on Form F-4 (the “Registration Statement”), relating to their previously announced business combination, has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) on June 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608520188/en/ IQM Radiance quantum computer The extraordinary general meeting of RAAQ’s shareholders in connection with the proposed business combination (the “Extraordinary General Meeting”) will be held on June 25, 2026. The proxy statement/prospectus relating to the Extraordinary General Meeting was mailed to RAAQ’s shareholders of record
Monster Hunter Wilds: Ascendance to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Monster Hunter: World, released in 2018, surpassed 30 million units as Capcom looks to expand its global user base – Capcom Co., Ltd. (TOKYO:9697) today announced that Monster Hunter Wilds: Ascendance, a massive expansion for Monster Hunter Wilds, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608183725/en/ Monster Hunter Wilds Ascendance key art Monster Hunter Wilds: Ascendance is a massive expansion (paid content) for Monster Hunter Wilds, which was released in February 2025. As a continuation of the main game’s story, the expansion will further deepen the gameplay experience with new content including new quest ranks, locales, additional monsters and expanded weapon actions through new gameplay features. The company is currently developing the title for release in 2027. Capcom is also developing Monster Hunter Wilds for Nintendo Switch™ 2 in addition to the existing platforms. Furthe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom